Oncology Featured Articles
-
Life Science Venture Funding Drops
9/28/2012
The economic recession made its impact on life science investments and until there is a change in the economy investment and venture capital firms will remain cautious and conservative.
-
Clinical Trials Ontario: Harnessing Its Research Expertise
9/28/2012
As clinical trial placements began to decline after 2008, Ontario became the first Canadian governmental entity to fund an organization to change the clinical trials landscape, Clinical Trials Ontario (CTO).
-
Can Rapid Mobile Diagnostics Speed Up Clinical Trials And Regulatory Reviews?
8/30/2012
As a new technological space containing all the alternatives, the most practical and immediate application for Rapid Mobile Diagnostics (RMDx) may be in clinical trials.
-
What’s The Buzz Around Outsourcing Oncology?
6/28/2012
Sponsors are increasing interests in oncology as a therapeutic focus in their drug development pipelines, according to Nice Insight’s pharmaceutical and biotechnology outsourcing survey. By Kate Hammeke, research manager, Nice Insight
-
Integrative Biology: At The Tipping Point
10/7/2011
I recently met Gustavo Salem, VP and general manager of the Biological Systems Division at Agilent Technologies. Salem believes integrative biology is at a tipping point for producing major breakthroughs in the drug development. By Rob Wright, Chief Editor, Life Science Leader magazine
-
Breast Cancer Vaccine - Holds Promise For Several Players
9/15/2011
I came across a headline in one of my news feeds announcing the FDA clearing the way for RXi Pharmaceuticals to move forward with plans for final-stage testing of a cancer vaccine. This might not seem like big news.
-
The Future Of Cancer Clinical Trials Hold Promise Thanks To Oncolytic Viruses
8/9/2011
Chemotherapy is now often used in combination with other treatments that have different mechanisms for attacking and killing cancer cells. Doctors must be cautious when combining treatments to ensure that the regimen does not become too toxic for patients to tolerate. The goal is to introduce drugs that can be used synergistically with chemotherapy to not only extend life, but to improve quality of life while undergoing treatment. By Douglas W. Loe, PhD, MBA